Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with stable coronary artery disease, it remains unclear whether an initial management strategy of percutaneous coronary intervention (PCI) with intensive pharmacologic therapy and lifestyle intervention (optimal medical therapy) is superior to optimal medical therapy alone in reducing the risk of cardiovascular events. METHODS: We conducted a randomized trial involving 2287 patients who had objective evidence of myocardial ischemia and significant coronary artery disease at 50 U.S. and Canadian centers. Between 1999 and 2004, we assigned 1149 patients to undergo PCI with optimal medical therapy (PCI group) and 1138 to receive optimal medical therapy alone (medical-therapy group). The primary outcome was death from any cause and nonfatal myocardial infarction during a follow-up period of 2.5 to 7.0 years (median, 4.6). RESULTS: There were 211 primary events in the PCI group and 202 events in the medical-therapy group. The 4.6-year cumulative primary-event rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (hazard ratio for the PCI group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%; hazard ratio, 1.05; 95% CI, 0.87 to 1.27; P=0.62); hospitalization for acute coronary syndrome (12.4% vs. 11.8%; hazard ratio, 1.07; 95% CI, 0.84 to 1.37; P=0.56); or myocardial infarction (13.2% vs. 12.3%; hazard ratio, 1.13; 95% CI, 0.89 to 1.43; P=0.33). CONCLUSIONS: As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy. (ClinicalTrials.gov number, NCT00007657 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended (Fig. 10.5), in part because these high-risk people should already be receiving intensive medical therapy-an approach that provides benefits similar to those of invasive revascularization (208,209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended, in part because these high-risk people should already be receiving intensive medical therapy—an approach that provides benefits similar to those of invasive revascularization (197,198).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [197]
In the citing paper
“OMT with risk modification remains the foundation of management in patients with T2DM and CAD.263,264”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [264]
In the citing paper
“these high-risk patients should already be receiving intensive medical therapy -an approach that provides benefi t similar to invasive revascularization (172,173).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [172]
In the citing paper
“The screening of asymptomatic patients remains controversial, especially as intensive medical therapy indicated in diabetic patients at high risk for CVD has an increasing evidence base for providing equal outcomes to invasive revascularization, including in diabetic patients (222).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [222]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Self-citationThe SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Keeley, E. C., Boura, J. A., & Grines, C. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12113-7 · Cited by 4,361
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
Cited by
Items 901–1,000 of 1,002
Fractional flow reserve: a clinical perspective
Corcoran, D. S., Hennigan, B., & Berry, C. (2017) · International journal of cardiac imaging · doi:10.1007/s10554-017-1159-2 · Cited by 32
“A key sub-study of COURAGE, demonstrated that patients with evidence of inducible ischaemia on SPECT imaging (≥10% ischaemic myocardium) (i.e.”
MethodInfluentialBrilakis, E. S., Mashayekhi, K., & Burke, M. N. (2019) · Circulation · doi:10.1161/circulationaha.119.039835 · Cited by 32
HDL Hypothesis: Where Do We Stand Now?
Tariq, S. M., Sidhu, M. S., Toth, P. P., & Boden, W. E. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0398-0 · Cited by 31
Self-citationRibichini, F., Tomai, F., De Luca, G., Boccuzzi, G., Presbitero, P., Pesarini, G., Ferrero, V., Ghini, A. S., Abukaresh, R., Aurigemma, C., et al. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.027 · Cited by 31
Thomas, M. P., Moscucci, M. M., Smith, D. E., Aronow, H. D., Share, D. A., Kraft, P. L., & Gurm, H. S. (2011) · Clinical Cardiology · doi:10.1002/clc.20926 · Cited by 31
Nørgaard, B. L., Jensen, J. M., & Leipsic, J. A. (2015) · European Radiology · doi:10.1007/s00330-015-3619-1 · Cited by 31
“However, The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial supplied evidence that anatomic assessment by ICA alone does not improve prognosis [1].”
MethodShared Decision Making Guidance Reminders in Practice (SDM-GRIP)
Holmes-Rovner, M. M., Kelly‐Blake, K., Dwamena, F. C., Dontje, K., HENRY, R. C., Olomu, A. B., Rovner, D. R., & Rothert, M. L. (2011) · Patient Education and Counseling · doi:10.1016/j.pec.2010.12.028 · Cited by 31
Korosoglou, G., Giuşcă, S., Gitsioudis, G., Erbel, C., & Katus, H. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00291 · Cited by 32
“Therefore, the currently used revascularization strategies may do little to prevent future coronary events (Libby, 2001; Boden et al., 2007).”
MethodWhat can we learn from oncology surgical trials?
Évrard, S., McKelvie‐Sebileau, P., van de Velde, C. J. �., Nordlinger, B., & Poston, G. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.176 · Cited by 32
Barbero, U., D’Ascenzo, F., Nijhoff, F., Moretti, C., Biondi‐Zoccai, G., Mennuni, M. G., Capodanno, D., Lococo, M. F., Lipinski, M. J., & Gaïta, F. (2016) · Scientifica · doi:10.1155/2016/3769152 · Cited by 39
Chang, M., Ahn, J., Kim, N., Lee, P. H., Roh, J., Yoon, S., Kang, S., Lee, S., Kim, Y., Lee, C. W., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.020 · Cited by 31
Shaw, L. J., Blankstein, R., Jacobs, J. E., Leipsic, J. A., Kwong, R. Y. K., Taqueti, V. R., Beanlands, R. S., Mieres, J. H., Flamm, S. D., Gerber, T. C., et al. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/hci.0000000000000017 · Cited by 32
Self-citationCardiovascular Disease in Dialysis Patients
Jegatheesan, D. K., Yang, W., Krishnasamy, R., Hawley, C. M., & Johnson, D. W. (2018) · InTech eBooks · doi:10.5772/intechopen.70362 · Cited by 32
“Coronary intervention does not appear to improve survival in asymptomatic individuals in the general population [185].”
BackgroundFrom CT to artificial intelligence for complex assessment of plaque-associated risk
Opincariu, D., Benedek, T., Chițu, M., Raț, N., & Benedek, I. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-01926-1 · Cited by 34
Kinnel, M., Sanguineti, F., Pezel, T., Unterseeh, T., Hovasse, T., Toupin, S., Landon, V., Champagne, S., Morice, M., Garot, P., et al. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa316 · Cited by 31
Coronary Magnetic Resonance Angiography in Chronic Coronary Syndromes
Hajhosseiny, R., Muñoz, C., da Cruz, G. J. L., Khamis, R., Kim, W. Y., Prieto, C., & Botnar, R. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.682924 · Cited by 32
“best medical therapy on hard end point outcomes such as death or myocardial infarction in patients that were angiographically identified to have significant CAD (83).”
BackgroundUse of Stress Testing and Diagnostic Catheterization After Coronary Stenting
Shah, B. R., McCoy, L. A., Federspiel, J. J., Mudrick, D. W., Cowper, P. A., Masoudi, F. A., Lytle, B. L., Green, C. L., & Douglas, P. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.093 · Cited by 31
Bangalore, S. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0264-7 · Cited by 31
“While several randomized trials in the past decade have evaluated revascularization or medical therapy alone for patients with stable ischemic heart disease, the majority of these trials have largely excluded patients with CKD/ESRD or included a very small proportion of these patients.(22,23) The management of patient…”
BackgroundThe epistemology of patient safety research
Runciman, W. B., Baker, G. R., Michel, P., Larizgoitia, I., Lilford, R. J., Andermann, A. A. J., Flin, R. H., & Weeks, W. B. (2008) · International Journal of Evidence-Based Healthcare · doi:10.1097/01258363-200812000-00008 · Cited by 46
Sakamoto, T., & Ogawa, H. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0537 · Cited by 31
Revascularization for Coronary Artery Disease: Stents Versus Bypass Surgery
King, S. B., Marshall, J. J., & Tummala, P. E. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.032309.063039 · Cited by 31
“The COURAGE trial (56) studied 2287 patients who had stable CAD by coronary angiography and objective evidence of myocardial ischemia on stress testing.”
Optimal Treatment Strategies in Patients with Chronic Kidney Disease and Coronary Artery Disease
Volodarskiy, A., Kumar, S., Amin, S., & Bangalore, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.046 · Cited by 31
Pickard, S. S., Gauvreau, K., Gurvitz, M. Z., Gagne, J. J., Opotowsky, A. R., Jenkins, K. J., & Prakash, A. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.08.051 · Cited by 31
Wijns, W. C., Bruyne, B. D., & Vanhoenacker, P. K. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.04.016 · Cited by 31
Ranolazine: a new approach to treating an old problem.
Reddy, B. M., WEINTRAUB, H. S., & Schwartzbard, A. Z. (2010) · PubMed Central · Cited by 30
Fiechter, M., Ghadri, J. R., Wolfrum, M., Kuest, S. M., Pazhenkottil, A. P., Nkoulou, R. N., Herzog, B. A., Gebhard, C., Fuchs, T. A., Gaemperli, O., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1999-2 · Cited by 30
Lindstaedt, M., Halilcavusogullari, Y., Yazar, A., Holland‐Letz, T., Bojara, W., Mügge, A., & Germing, A. (2010) · Clinical Cardiology · doi:10.1002/clc.20693 · Cited by 33
The Enduring Legacy of Sham-Controlled Trials of Internal Mammary Artery Ligation
Miller, F. G. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2012.09.002 · Cited by 31
Rothberg, M. B., Scherer, L. D., Kashef, M. A., Coylewright, M. J., Ting, H. H., Hu, B., & Zikmund‐Fisher, B. J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3331 · Cited by 30
Yoshinaga, K., Manabe, O., & Tamaki, N. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1290 · Cited by 30
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30
“The COURAGE trial (Boden et al. 2007) randomized 2,287 patients with SIHD to an initial strategy of PCI plus optimal medical therapy (OMT) versus OMT alone.”
MethodInfluentialSelf-citationBishawi, M. M., Hattler, B. G. J., Almassi, G. H., Spertus, J. A., Quin, J. A., Collins, J. F., Grover, F. L., & Shroyer, A. L. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.12.014 · Cited by 34
“Previous publications have reported SAQ changes after percuta neous coronary intervention (PCI) and CABG proce dures,(6,7) with clinically significant changes within an individual considered to be ≥20 points for the SAQ-AF scale, ≥8 points for the SAQ-PL domain and ≥16 points for the SAQ-QoL score.(8,9) The VR-36 like…”
BackgroundSelf-citationLaukkanen, J. A., & Kunutsor, S. K. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.10.016 · Cited by 35
Coronary CT angiography: a guide to examination, interpretation, and clinical indications
Cademartiri, F., Casolo, G., Clemente, A., Seitun, S., Mantini, C., Bossone, E., Saba, L., Sverzellati, N., Nistri, S., Punzo, B., et al. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1915132 · Cited by 36
Buckley, B. J. R., de Koning, I. A., Harrison, S. L., Fazio‐Eynullayeva, E., Underhill, P., Kemps, H., Lip, G. Y. H., & Thijssen, D. H. J. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab191 · Cited by 33
Revascularization in stable coronary artery disease
Al-Lamee, R. K., Foley, M. J., Rajkumar, C., & Francis, D. P. (2022) · BMJ · doi:10.1136/bmj-2021-067085 · Cited by 37
Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020
Mastrocola, L. E., Amorim, B. J., Vitola, J. V., Brandão, S. C. S., Grossman, G. B., Lima, R. D. S. L., Lopes, R. W., Chalela, W. A., Carreira, L. C. T. F., de Araújo, J. R. N., et al. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200087 · Cited by 62
Wereski, R., Adamson, P. D., Daud, N. S. S., McDermott, M., Taggart, C., Bularga, A., Kimenai, D. M., Lowry, M. T. H., Tuck, C. E., Anand, A., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.046 · Cited by 37
Pilz, G., Patel, P., Fell, U., Ladapo, J. A., Rizzo, J. A., Fang, H., Gunnarsson, C., Heer, T., & Hoefling, B. (2010) · International journal of cardiac imaging · doi:10.1007/s10554-010-9645-9 · Cited by 30
“is not associated with an incremental survival benefit [20].”
BackgroundCoronary pressure-derived fractional flow reserve in the assessment of coronary artery stenoses
Kakouros, N., Rybicki, F. J., Mitsouras, D., & Miller, J. M. (2012) · European Radiology · doi:10.1007/s00330-012-2670-4 · Cited by 30
“All patients with significant lesions in one or more coronary vessels were randomised between OMT alone, or OMT plus FFRguided PCI.”
BackgroundInfluentialCoronary artery bypass graft vs. percutaneous coronary angioplasty: CABG on the rebound?
Taggart, D. P. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3282f001a2 · Cited by 30
Ko, W., Tranbaugh, R. F., Marmur, J. D., Supino, P. G., & BORER, J. S. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001446 · Cited by 28
Patel, D. B., Hamamdzic, D., Llano, R., Patel, D., Cheng, L., Fenning, R. S., Bannan, K., & Wilensky, R. L. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300710 · Cited by 30
Toor, I. S., Jaumdally, R. J., Lip, G. Y. H., Pagano, D., Dimitri, W. R., Millane, T. A., & Varma, C. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02776.x · Cited by 31
Hyperpolarised magnetic resonance for in vivo real-time metabolic imaging
Apps, A. P., Lau, J. Y. C., Peterzan, M. A., Neubauer, S., Tyler, D. J., & Rider, O. J. (2018) · Heart · doi:10.1136/heartjnl-2017-312356 · Cited by 30
Garzillo, C. L., Hueb, W. A., Gersh, B. J., Rezende, P. C., Lima, E. G., Favarato, D., Ramires, J. A. F., & Filho, R. K. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2227 · Cited by 30
Silber, S., Borggrefe, M., Böhm, M., Hoffmeister, H.-M., Dietz, R., Ertl, G., & Heusch, G. (2007) · Der Kardiologe · doi:10.1007/s12181-007-0012-6 · Cited by 43
Surgical Explantation of Failed Transcatheter Aortic Valve Replacement
Zaid, S., Hirji, S. A., Bapat, V., Denti, P., Modine, T., Nguyen, T. C., Mack, M. J., Reardon, M. J., Kaneko, T., Tang, G. H. L., et al. (2023) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2023.05.036 · Cited by 29
Chronic total occlusion: To treat or not to treat
Bardají, A. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i7.621 · Cited by 29
Mentz, R. J., Fiuzat, M., Shaw, L. K., Phillips, H. R., Borges‐Neto, S., Felker, G. M., & O’Connor, C. M. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.12.021 · Cited by 31
Self-citationSudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?
Katritsis, D. G., & Josephson, M. E. (2012) · EP Europace · doi:10.1093/europace/eus001 · Cited by 33
Matsuo, S., Nakajima, K., Yamasaki, Y., Kashiwagi, A., & Nishimura, T. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0098 · Cited by 29
Luca, L. D., Temporelli, P. L., Lucci, D., Gonzini, L., Riccio, C., Colivicchi, F., Geraci, G., Formigli, D., Maras, P., Falcone, C., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317740663 · Cited by 29
Trimetazidine and Other Metabolic Modifiers
Guarini, G., Huqi, A., Cardiovascular Medicine Division, O. D. V., Morrone, D., Capozza, P., & Marzilli, M. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.15.2 · Cited by 31
Cardiac Imaging in the Post-ISCHEMIA Trial Era
Shaw, L. J., Kwong, R. Y. K., Nagel, E. C., Salerno, M., Jaffer, F. A., Blankstein, R., Dilsizian, V., Flachskampf, F. A., Grayburn, P. A., Leipsic, J. A., et al. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.05.001 · Cited by 33
Self-citationCT-Derived Fractional Flow Reserve (CT-FFR) in the Evaluation of Coronary Artery Disease
Khav, N., Ihdayhid, A. R., & Ko, B. S. H. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.05.099 · Cited by 29
Myocardial Ischemia in the Management of Chronic Coronary Artery Disease: Past and Present
Gibbons, R. J. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.011615 · Cited by 35
Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes
Monda, E., Palmiero, G., Lioncino, M., Rubino, M., Cirillo, A., Fusco, A., Caiazza, M., Verrillo, F., Diana, G., Mauriello, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030868 · Cited by 29
“Nevertheless, data from large RCTs [90,91] have shown conflicting results regarding the benefit of reperfusion compared with medical therapy [92].”
ResultGersh, B. J. (2009) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79489-4 · Cited by 29
Ganesananthan, S., Rajkumar, C., Foley, M. J., Thompson, D., Nowbar, A. N., Seligman, H., Petraco, R., Sen, S., Nijjer, S. S., Thom, S., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac260 · Cited by 30
“Primary analysis of the ISCHAEMIA trial 48 and previously from COURAGE 49 have suggested that coronary revascularization, in addition to medical therapy, does not lead to reduction in all-cause mortality or risk of ischaemic cardiovascular events.”
MethodZhou, W., Sin, J., Yan, A. T.-K., Wang, H., Lu, J., Li, Y., Kim, P. J., Patel, A. R., & Ng, M. (2023) · Diagnostics · doi:10.3390/diagnostics13030524 · Cited by 33
“Quantitatively, an ischemia burden of ≥1.5 segments or ≥10% myocardium with MPR 1.5 was proposed as a CMR indicator for revascularisation, as it most strongly predicted MACEs [41,42].”
InfluentialWaller, A. H., Blankstein, R., Kwong, R. Y. K., & Carli, M. F. D. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0483-6 · Cited by 33
Hasokawa, M., Shinohara, M., Tsugawa, H., Bamba, T., Fukusaki, E., Nishiumi, S., Nishimura, K., Yoshida, M., Ishida, T., & Hirata, K. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-0622 · Cited by 29
Patient-Centered Medicine: The Next Phase in Health Care
Krumholz, H. M. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962217 · Cited by 32
Xue, Y., Wang, L., Liu, H., Qi, X.-W., Wang, X., & Ren, H.-Z. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6056-9 · Cited by 29
Sendon, J. L. L., Lee, S., Cheng, M. L., Ben‐Yehuda, O., & (for the CARISA study investigators) (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450133 · Cited by 29
Kovacic, J. C., & Fuster, V. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.173 · Cited by 29
Bleeding during percutaneous intervention: tailoring the approach to minimise risk
Kinnaird, T. D., Anderson, R. A., HILL, J. T., & Thomas, M. (2008) · Heart · doi:10.1136/hrt.2007.131284 · Cited by 37
Cho, Y., Shimura, S., Aki, A., Furuya, H., Okada, K., & Ueda, T. (2016) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivw057 · Cited by 29
“It is recognized that PCI offers immediate relief of angina in patients with stable coronary disease although it does not reduce the risk of myocardial infarction (MI) or death [11–13].”
BackgroundThe vulnerable atherosclerotic plaque: in vivo identification and potential therapeutic avenues
Adamson, P. D., Dweck, M. R., & Newby, D. E. (2015) · Heart · doi:10.1136/heartjnl-2014-307099 · Cited by 30
Morrow, D. A., & Boden, W. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00057-3 · Cited by 31
Self-citationBeckie, T. M., Fletcher, G. F., Beckstead, J. W., Schocken, D. D., & Evans, M. E. (2008) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/01.hcr.0000311510.16226.6e · Cited by 31
Wanitschek, M. M., Dörler, J., & Alber, H. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605394 · Cited by 30
Delewi, R., Aarts, H. M., Broeze, G. M., Hemelrijk, K. I., van Ginkel, D. J., Versteeg, G. A. A., Grundeken, M. J., Claessen, B. E. P. M., Tonino, P. A. L., Schotborgh, C. E., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00308-9 · Cited by 28
Lazzeri, C., Valente, S., Chiostri, M., Picariello, C., & Gensini, G. F. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164110396744 · Cited by 28
“Failure PCI was defined as resulting in TIMI grade 0 to 2 flow, regardless of the residual stenosis.(19) The diagnosis of STEMI was based on the criteria of the American College of Cardiology/American Heart Association.”
MethodBenefits of and safety concerns associated with drug-eluting coronary stents
Garg, S., & Serruys, P. W. J. C. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.138 · Cited by 28
Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials
Bangalore, S., Gupta, N., Généreux, P., Guo, Y., Pancholy, S. B., & Feit, F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.01.053 · Cited by 28
Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose
Spector, R., & Snapinn, S. M. (2011) · Pharmacology · doi:10.1159/000322999 · Cited by 32
Aldweib, N., Negishi, K., Hachamovitch, R., Jaber, W. A., Seicean, S., & Marwick, T. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.043 · Cited by 28
“CAD coronary artery disease; CVA cardiovascular accident; DBP diastolic blood pressure; V left ventricular; SDS summed difference score; SVT supraventricular tachycardia; TIA ransient ischemic attack; V-FIB ventricular fibrillation; VT ventricular tachycardia; other bbreviations as in Table 1.”
ResultInfluentialBertoluci, M. C., Netto, A. P., Pires, A. C., Pesaro, A. E. P., Schaan, B. D., Caramelli, B., Polanczyk, C. A., Junior, C. V. S., Gualandro, D. M., Malerbi, D. A. C., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-58 · Cited by 34
Pereira, H., Teles, R. C., Costa, M. A. D. S., da Silva, P. C., Ferreira, R. C., Ribeiro, V. D. G., de Oliveira, R. S., Abreu, P. F. E., Carvalho, H. C., Marques, J. H. S., et al. (2015) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2015.06.005 · Cited by 28
Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
Brie, D. M., Penson, P. E., Șerban, M.-C., Toth, P. P., Simonton, C. A., Serruys, P. W. J. C., & Banach, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.027 · Cited by 30
“Incidence of angina recurrence at 1 year after PCI is high, as demonstrated in several studies, including the Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes (FREEDOM) trial [119], the Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the…”
The Impact of the Geometric Characteristics on the Hemodynamics in the Stenotic Coronary Artery
Peng, C., Wang, X., Xian, Z., Liu, X., Huang, W., Xu, P., & Wang, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157490 · Cited by 30
“The stents and scaffolds implanted during invasive treatment of coronary stenosis via percutaneous coronary intervention (PCI) procedures consider the curvature because the implantation alters blood rheology, leading to early and late stent failure [32, 33].”
BackgroundRodríguez‐Mañero, M., Cordero, A., Kreidieh, O., García‐Acuña, J. M., Seijas‐Amigo, J., Agra-Bermejo, R. M., Abou-Jokh, C., Rodríguez, L. Á., Álvarez-Iglesias, D., López‐Palop, R., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.084 · Cited by 28
Revascularization in stable coronary disease: evidence and uncertainties
Katritsis, D. G., Mark, D. B., & Gersh, B. J. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0006-z · Cited by 30
Hamon, M., Geindreau, D., Guittet, L., Bauters, C., & Hamon, M. (2019) · European Radiology · doi:10.1007/s00330-018-5919-8 · Cited by 29
Sharir, T., Hollander, I., Hemo, B., Tsamir, J., Yefremov, N., Bojko, A., Prokhorov, V., Pinskiy, M., Slomka, P. J., & Amos, K. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-019-01932-4 · Cited by 29
Vij, A., Kassab, K., Chawla, H., Kaur, A., Kodumuri, V., Jolly, N., & Doukky, R. (2021) · Clinical Cardiology · doi:10.1002/clc.23592 · Cited by 29
Relief of Ischemia in Ischemic Cardiomyopathy
Moroni, F., Gertz, Z. M., & Azzalini, L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01520-4 · Cited by 30
Clinical overview of diabetes mellitus as a risk factor for cardiovascular death
Abuelgasim, E., Shah, S., Abuelgasim, B., Soni, N., Thomas, A., Elgasim, M., & Harky, A. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202038 · Cited by 32
“On the other hand, opponents argue for optimal medical treatment without screening, as revascularization has not been shown convincingly to decrease cardiovascular events in patient with diabetes [91, 92].”
BackgroundCauses of cardiovascular and noncardiovascular death in the ISCHEMIA trial
Sidhu, M. S., Alexander, K. P., Huang, Z., O’Brien, S. M., CHAITMAN, B. R., Stone, G. W., Newman, J. D., Boden, W. E., Maggioni, A. P., Steg, P. G., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.01.017 · Cited by 30
Self-citationO’Driscoll, J. M., Hawkes, W., Beqiri, A., Mumith, A., Parker, A., Upton, R., McCourt, A., Woodward, W. J., Dockerill, C., Sabharwal, N. K., et al. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac059 · Cited by 30
“This is potentially salient after findings favouring conservative patient management strategies (e.g. COURAGE 17 and ORBITA, 18 ) especially in cases of less severe myocardial ischaemia under stress.”
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies
Leong, D. P., Cirne, F., Aghel, N., Vila, R. C. B., Cavalli, G. D., Ellis, P. M., Healey, J. S., Whitlock, R. P., Khalaf, D., Mian, H. S., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.05.008 · Cited by 31
“Revascularization for stable multivessel coronary disease may not decrease the risk of death or myocardial infarction when performed in addition to optimal medical therapy.(23,24) However, revascularization can decrease angina in individuals with stable coronary artery disease and inducible myocardial ischemia.”
BackgroundSecondary prevention strategies for coronary heart disease
Weiner, S. D., & Rabbani, L. E. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0381-8 · Cited by 29
“The importance of optimal medical therapy was only further emphasized with the results of the COURAGE trial demonstrating that as an initial management strategy in patients with stable CHD, percutaneous coronary intervention did not reduce the risk of death, MI, or other major cardiovascular events when added to optim…”
Takashima, H., Waseda, K., Gosho, M., Kurita, A., Ando, H., Sakurai, S., Maeda, K., Kumagai, S., Suzuki, A., & Amano, T. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.11.004 · Cited by 28
Revascularization strategies for patients with stable coronary artery disease
Iqbal, J., & Serruys, P. W. J. C. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12243 · Cited by 30
Lee, C., Ng, W.-Y., Hau, W., Ho, H., Tai, B., Chan, M. Y., Richards, M., & Tan, H. C. (2013) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.3266 · Cited by 29
Bjorck, L. M., Wallentin, L., Stenestrand, U., Lappas, G., & Rosengren, A. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.203 · Cited by 34
Grace, S. L., Chessex, C., Arthur, H. M., Chan, S., Cyr, C., Dafoe, W. A., Juneau, M., OH, P. I., & Suskin, N. (2011) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e318219721f · Cited by 27
New applications for noninvasive cardiac imaging: dual-source computed tomography
Rist, C., Johnson, T. R. C., Becker, C. R., Reiser, M. F., & Nikolaou, K. (2007) · European Radiology Supplements · doi:10.1007/s10406-007-0224-7 · Cited by 28
“compared to an optimal medical therapy [39].”
Metadata
- Authors
- Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., Spertus, J. A., Berman, D. S., Mancini, G. B. J., & Weintraub, W. S.
- Affiliations
- VA Western New York Healthcare System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1503-1516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160414137
- Cited by
- 4,699
- References
- 49
- Citations by year
- 2026: 111 · 2025: 142 · 2024: 150 · 2023: 166 · 2022: 197 · 2021: 255 · 2020: 282 · 2019: 202 · 2018: 227 · 2017: 211 · 2016: 276 · 2015: 263 · 2014: 295 · 2013: 309 · 2012: 322
- FWCI
- 315.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- optimal medical therapy, percutaneous coronary intervention, stable coronary artery disease, myocardial ischemia, cardiovascular events, myocardial infarction, mortality, lifestyle intervention, coronary artery disease
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Angina Pectoris, Angiotensin-Converting Enzyme Inhibitors, Anticholesteremic Agents, Antihypertensive Agents, Combined Modality Therapy, Coronary Disease, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk Factors, Angioplasty, Balloon, Coronary, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.